

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

DIAGNOSTICS ASSESSMENT PROGRAMME

Equality impact assessment – Scoping

**EGFR-TK mutation testing in adults with locally advanced or
metastatic non-small-cell lung cancer**

The impact on equality has been assessed during this assessment according to the principles of the NICE Equality scheme.

- | |
|--|
| 1. Have any potential equality issues been identified during the scoping process (scoping workshop discussion, assessment subgroup discussion), and, if so, what are they? |
|--|

The frequency of EGFR-TK mutations is highest in Asian women who have never smoked and have tumours with adenocarcinoma histology.
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
|---|

This issue does not need to be addressed by the Committee as EGFR-TK mutation testing is carried out on all eligible patients irrespective of gender, ethnicity and smoking status, to ensure that all eligible patients who could benefit from treatment with an anti-EGFR TKI are identified (as recommended in technology appraisal 192).
--

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No

- | |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made? |
|--|

No

Approved by Associate Director (name): ...Nick Crabb.....

Date: 23 July 2012